While OSM has historically been identified as an inhibitor of breast cancer proliferation (15, 102, 103), overexpression of OSM and OSMRβ has been linked to decreased overall survival, decreased reoccurrence-free survival and decreased metastasis free survival in breast cancer patients (104–107). Here, OSM is linked to breast cancer.